Although response rates were higher in patients with EGFR mutant tumours, the use of erlotinib in molecularly unselected NSCLC patients after failure of one or two lines of chemotherapy demonstrated modest survival and quality of life benefit compared to placebo in all patients [17, 18]. Here, EGFR is linked to non-small cell lung carcinoma.